Alexion says data presented demonstrating the clinical benefits of Soliris

theflyonthewall.com

Alexion Pharmaceuticals announced that researchers presented data from four clinical trials, all demonstrating the clinical benefits of Soliris, eculizumab, for the treatment of atypical hemolytic uremic syndrome, aHUS, a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death. Soliris is the first and only approved safe and effective treatment for pediatric and adult patients with aHUS. In two large, prospective, multinational studies, Soliris inhibited systemic complement-mediated thrombotic microangiopathy, TMA, the formation of blood clots in small blood vessels throughout the bod, and improved renal function in both pediatric and adult patients with aHUS.1,2 The data were presented at Kidney Week 2013, the annual meeting of the American Society of Nephrology, ASN, in Atlanta.

Rates

View Comments (0)